Caradigm™, formerly Amalga Life Sciences, is a healthcare analytics and population health company dedicated to helping organizations improve care, reduce costs, and manage risk. Caradigm analytics solutions provide insight into patients, populations, and performance, enabling healthcare organizations to understand their clinical and financial risk and identify the actions needed to address it. Caradigm population health solutions enable teams to deliver the appropriate care to patients through effective coordination and patient engagement, helping to improve outcomes and financial results. The key to Caradigm analytics and population health solutions is a rich set of clinical, operational, and financial data delivered to healthcare professionals within their workflows in near-real time. This data asset serves as the foundation for a growing number of innovative healthcare applications developed by Caradigm and industry partners, providing rapid incremental value to customers.

On June 1, 2009 Microsoft Corp. announced that it has signed an agreement with Merck & Co. Inc. to acquire certain assets of Rosetta Biosoftware, a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co. Inc.